Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19

Liang, 2020, Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China, Lancet Oncol, 21, 335, 10.1016/S1470-2045(20)30096-6 Wu, 2020, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA, 323, 1239, 10.1001/jama.2020.2648 Siegel, 2020, Cancer statistics, 2020, CA: Cancer J Clin, 70, 7 Mohler, 2019, Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology, J Natl Compr Cancer Netw, 17, 479, 10.6004/jnccn.2019.0023 van Doremalen, 2020, Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1, New Engl J Med, 10.1056/NEJMc2004973 Hamdy, 2016, 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer, N Engl J Med, 375, 1415, 10.1056/NEJMoa1606220 Klotz, 2015, Long-term follow-up of a large active surveillance cohort of patients with prostate cancer, J Clin Oncol, 33, 272, 10.1200/JCO.2014.55.1192 Pisansky, 2015, Duration of androgen suppression before radiotherapy for localized prostate cancer: Radiation therapy oncology group randomized clinical trial 9910, J Clin Oncol, 33, 332, 10.1200/JCO.2014.58.0662 Morris, 2017, Int J Radiat Oncol Biol Phys, 98, 275, 10.1016/j.ijrobp.2016.11.026 Zapatero, 2016, Late radiation and cardiovascular adverse effects after androgen deprivation and high-dose radiation therapy in prostate cancer: Results from the DART 01/05 randomized phase 3 trial, Int J Radiat Oncol Biol Phys, 96, 341, 10.1016/j.ijrobp.2016.06.2445 Spratt, 2019, Two years of anti-androgen treatment increases other-cause mortality in men receiving early salvage radiotherapy: A secondary analysis of the NRG Oncology/RTOG 9601 randomized phase III trial, Int J Radiat Oncol Biol Phys, 105, 680, 10.1016/j.ijrobp.2019.08.029 Iversen, 2004, Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6, J Urol, 172, 1871, 10.1097/01.ju.0000139719.99825.54 Kneebone, 2019, A phase III multi-centre randomised trial comparing adjuvant versus early salvage radiotherapy following a radical prostatectomy: Results of the TROG 08.03 and ANZUP “RAVES” Trial, Int J Radiat Oncol Biol Phys, 105, S37, 10.1016/j.ijrobp.2019.06.456 Brand, 2019, Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial, Lancet Oncol, 20, 1531, 10.1016/S1470-2045(19)30569-8 Dearnaley, 2016, Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol, 17, 1047, 10.1016/S1470-2045(16)30102-4 Chin, 2020, Ten-year outcomes of moderately hypofractionated salvage postprostatectomy radiation therapy and external validation of a contemporary multivariable nomogram for biochemical failure, Int J Radiat Oncol Biol Phys Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3 Widmark, 2019, Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial, Lancet, 394, 385, 10.1016/S0140-6736(19)31131-6 Widmark, 2009, Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial, Lancet, 373, 301, 10.1016/S0140-6736(08)61815-2